UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

 

 

FORM 8-K

 

 

CURRENT REPORT

Pursuant to Section 13 or 15(d) of the

Securities Exchange Act of 1934

 

Date of Report (Date of earliest event reported):  May 31, 2019

 

 

APPLIED THERAPEUTICS, INC.

(Exact name of registrant as specified in its charter)

 

 

 

 

Registrant’s telephone number, including area code:  (212) 220-9319

 

Not Applicable

(Former name or former address, if changed since last report.)

 

 

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):

 

o                 Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

 

o                 Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

 

o                 Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

 

o                 Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

 

Securities registered pursuant to Section 12(b) of the Act:

 

 

Indicate by check mark whether the registrant is an emerging growth company as defined in as defined in Rule 405 of the Securities Act of 1933 (§ 230.405 of this chapter) or Rule 12b–2 of the Securities Exchange Act of 1934 (§ 240.12b–2 of this chapter).

 

Emerging growth company x

 

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act.  x

 

 

 

Item 5.02                                           Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers.

 

On May 31, 2019, Les Funtleyder, former Interim Chief Financial Officer (“CFO”) and member of the Board of Directors of Applied Therapeutics, Inc. (the “Company”), entered in to a separation agreement (the “Separation Agreement”) for the termination of his employment, effective as of May 31, 2019. Mr. Funtleyder will remain a  Class I director of the Company. The Separation Agreement memorializes the terms of his severance arrangements with the Company. Pursuant to the Separation Agreement, Mr. Funtleyder will receive, as severance, accelerated vesting of 100% of his unvested options granted to him under his Employment Agreement, dated December 26, 2018, and six months of COBRA coverage. Mr. Funtleyder has agreed to non-solicit and non-compete covenants, as well as executed a general release of claims in connection therewith.

 

The foregoing description of the terms of the Separation Agreement does not purport to be complete and is qualified in its entirety by the full text of the Separation Agreement. The Company intends to file the Separation Agreement with the Company’s Quarterly Report on Form 10-Q for the quarter ending March 31, 2019.

 

2

 

SIGNATURES

 

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

 

 

	APPLIED THERAPEUTICS, INC.
	By:	/s/ Mark Vignola
		Mark Vignola, Ph.D.
		Chief Financial Officer
Dated: June 6, 2019

 

3